Composition with weight loss effect, preparation method and application
Through the compositions of Chinese medicinal materials such as Pu'er tea, Salvia miltiorrhiza, Astragalus, Poria, lotus leaves and senna, combined with the treatment of auxiliary materials, the existing traditional Chinese medicine weight loss composition has been solved, and the high cost and toxic side effects have been achieved, achieving high efficiency and health weight loss and blood lipid-lowering effect.
Patent Information
- Application Number
- CN202411198066.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-29
AI Technical Summary
The existing traditional Chinese medicine weight loss composition has complex composition and high cost, and it is difficult to achieve weight loss effects with good therapeutic effects, small toxic side effects and low cost.
Using compositions of Chinese medicinal materials such as Pu'er tea, Salvia miltiorrhiza, Astragalus, Poria, lotus leaves and senna leaves, through the concentration and enzymatic treatment of the extract, combined with auxiliary materials such as dextrin, citric acid and stevioside, to form a weight-loss effect. Composition.
It has achieved significant weight loss effects, while inhibiting obesity complications such as constipation and hyperlipidemia. It has efficient and healthy weight loss effects, and has reduced cholesterol, triglycerides, etc., improving atherosclerosis and liver function.
Smart Images

Figure SMS_1 
Figure SMS_4 
Figure SMS_8
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a composition with weight loss effect, a preparation method and application thereof. Background Art
[0002] Obesity is a chronic metabolic disease caused by multiple factors, characterized by an increase in the volume and number of fat cells in the body, resulting in an abnormal increase in the percentage of body fat to body weight and excessive fat deposition in certain parts. Obesity has become a social phenomenon with a complex pathogenesis and serious harm. Studies in recent years have shown that obesity is a disease caused by disorders in appetite and energy regulation, and is related to multiple factors such as genetics, environment, and dietary structure. Obesity has a clear relationship with type II diabetes, cardiovascular disease, and certain tumors.
[0003] In order to prevent or reduce the occurrence of obesity, in addition to enhancing self-care awareness and developing good living habits, it is also necessary to take certain intervention measures. Weight loss products have certain health functions, are highly safe, and can be taken for a long time. While losing weight, they can also significantly reduce the current risk factors of diabetes, hypertension, and cancer, which can greatly enhance the significance and value of early prevention.
[0004] There are many kinds of weight loss drugs on the market, but most of them have one deficiency or another. For example, some weight loss drugs can inhibit the hypothalamic feeding center and reduce appetite, but long-term and large-scale use will cause addiction, insomnia, hallucinations and other adverse reactions; laxative weight loss drugs achieve the purpose of weight loss by causing intermittent diarrhea, reducing stomach acid and appetite, but weight is easy to gain back after stopping the medication. If taken frequently, anemia and gastrointestinal diseases may occur.
[0005] Traditional Chinese medicine believes that obesity is a disease of mixed deficiency and excess, with deficiency as the root and excess as the symptom. Excess is mainly caused by phlegm, while deficiency is mainly caused by spleen. The so-called "fat people have more phlegm", "fat people have more dampness" and "fat people have more blood stasis" are the deficiency side of it. The fundamental reason is qi deficiency and poor yang qi circulation. Traditional Chinese medicine believes that the causes of obesity are: 1. Improper diet, eating fatty and sweet food, and overeating fatty and sweet food can damage the spleen and stomach, causing dysfunction of spleen and stomach transportation and transformation, leading to internal dampness and heat, heat and dampness stagnation, phlegm and dampness condensation, or retention in the skin, causing obesity. 2. Traditional Chinese medicine believes that "sitting for a long time hurts qi". Being still and motionless, qi and blood circulation is not smooth, spleen and stomach qi mechanism is stagnant, transportation and transformation function is disordered, and water and grain essence are blocked, turning into fat and phlegm, stagnating in tissues, skin, internal organs, and meridians, causing obesity.
[0006] Traditional Chinese medicine for weight loss is also known as natural medicine for weight loss. It is widely promoted because of its low toxicity and side effects and natural health. Existing studies have shown that traditional Chinese medicine has low toxicity and side effects in the treatment of obesity. By regulating the internal organs, it helps patients lose weight and improve their quality of life. It has gradually become a common treatment for obesity in clinical practice.
[0007] Chinese invention patent application CN104336241A discloses a Chinese herbal slimming tea, which is prepared from the following Chinese herbal raw materials: 5-12g of hawthorn, 5-12g of cassia seed, 5-10g of lotus leaf, 4-8g of processed Polygonum multiflorum, 3-6g of white chrysanthemum, 5-12g of lily, 4-8g of tangerine peel, 3-6g of mulberry leaf, and 3-6g of rose.
[0008] Chinese invention patent application CN103749824A discloses a gynostemma pentaphyllum hypoglycemic and blood pressure lowering health tea, the raw material composition and its weight proportion are: gynostemma pentaphyllum 10-50 parts, magnolia bark 10-20 parts, elsholtzia 10-20 parts, desmodium herba 10-20 parts, imperata rhizome 10-20 parts, tuckahoe 10-20 parts, salvia miltiorrhiza 10-20 parts, umbellate 10-20 parts, perilla frutescens 10-20 parts, coix seed 10-20 parts, mistletoe 10-20 parts, plantain seed 10-20 parts, trichosanthes root 10-20 parts, scutellaria baicalensis 10-20 parts, atractylodes macrocephala 10-20 parts, corn silk 10-20 parts.
[0009] However, the above-mentioned Chinese medicine composition has the disadvantages of complex composition and high cost, which limits its application. Therefore, it is of great significance to seek a composition with good therapeutic effect, small toxic side effects, simple composition and low cost and having weight loss effect. Summary of the invention
[0010] In view of the deficiencies in the prior art, the present invention provides a composition with weight loss effect, a preparation method and application.
[0011] In order to achieve the above-mentioned purpose of the present invention, the specific technical solution adopted by the present invention is:
[0012] A composition with weight loss effect, wherein the raw materials of the composition include: 4-6 parts of Pu'er tea, 4-5 parts of Salvia miltiorrhiza, 3-5 parts of Astragalus, 3-5 parts of Poria, 0.5-1.5 parts of lotus leaf and 0.2-0.4 parts of senna leaf by weight.
[0013] Preferably, the raw materials of the composition include, by weight: 5 parts of Pu'er tea, 4.5 parts of Salvia miltiorrhiza, 4 parts of Astragalus, 4 parts of Poria, 1 part of lotus leaf and 0.33 parts of senna leaf.
[0014] Preferably, the raw materials of the composition further include auxiliary materials, and the auxiliary materials include dextrin, citric acid and steviol glycoside.
[0015] Further preferably, the raw materials of the composition further include, by weight: 2-3 parts of dextrin, 0.1-0.2 parts of citric acid and 0.02-0.1 parts of steviol glycoside.
[0016] Pu'er tea has always been regarded as a health drink and is very popular among the people. Many ancient books have records about the effects of Pu'er tea. Zhao Xuemin of the Qing Dynasty wrote in "Supplement to Compendium of Materia Medica": "Pu'er tea paste can help digestion and reduce phlegm, clear the stomach and promote salivation. Pu'er tea, steamed into a ball, is sold in the Western Regions and is the best at digesting things. Pu'er tea tastes bitter and is astringent, it can remove greasiness, expel phlegm and relieve gas, and promote bowel movements." It can be seen that Pu'er tea has the effects of digesting food and removing toxins, removing greasiness, regulating qi and relieving bloating.
[0017] Danshen is the dried root and rhizome of Salvia miltiorrhiza Bunge, a plant of the genus Salvia in the family Lamiaceae. It is one of the most commonly used Chinese medicines for promoting blood circulation and removing blood stasis. It was first recorded in Shennong's Herbal Classic and has the effects of removing blood stasis and relieving pain, nourishing blood and calming the mind. It tastes bitter and is slightly cold. It enters the heart and liver meridians. It can promote blood circulation and remove blood stasis, promote menstruation and relieve pain, clear the heart and relieve restlessness, cool blood and eliminate carbuncle. It is used for chest pain, epigastric pain, accumulation of masses, heat arthralgia and pain, restlessness and insomnia, irregular menstruation, dysmenorrhea and amenorrhea, and sores and swelling.
[0018] Astragalus is the dried root of Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao or Astragalus membranaceus (Fisch.) Bge. of the Leguminosae family. It is sweet and slightly warm. It enters the lung and spleen meridians. It can replenish qi and raise yang, consolidate the exterior and stop sweating, promote diuresis and reduce swelling, promote the production of body fluid and nourish blood, relieve stagnation and relieve numbness, remove toxins and discharge pus, and heal sores and promote tissue regeneration. It is used for qi deficiency and fatigue, poor appetite and loose stools, sinking of qi in the middle, chronic diarrhea and prolapse of the anus, bloody stool and metrorrhagia, spontaneous sweating due to exterior deficiency, qi deficiency edema, internal heat and thirst, blood deficiency and sallow complexion, hemiplegia, pain and numbness in the arthralgia, carbuncle that is difficult to heal, and carbuncle that does not heal for a long time.
[0019] Poria cocos is the dried sclerotium of the fungus Poria cocos (Schw.) Wolf of the Polyporaceae family. It tastes sweet, light and neutral. It enters the heart, lung, spleen and kidney meridians. It can promote diuresis and eliminate dampness, strengthen the spleen and calm the mind. It is used for edema, oliguria, phlegm and fluid, palpitations, spleen deficiency, poor appetite, loose stools and diarrhea, restlessness, palpitations and insomnia.
[0020] Lotus leaf is the dried leaf of Nelumbo nucifera Gaertn., a plant of the Nymphaeaceae family. It tastes bitter and neutral. It enters the liver, spleen, and stomach meridians. It can clear away heat and dampness, promote the development of the clear yang, cool blood and stop bleeding. It is used for thirst due to summer heat, diarrhea due to summer dampness, diarrhea due to spleen deficiency, vomiting and bleeding due to blood heat, and metrorrhagia due to blood in stool. Lotus leaf charcoal is astringent, removes blood stasis and stops bleeding. It is used for hemorrhage and postpartum blood fainting.
[0021] Senna is the dried leaflets of Cassia angustifolia Vahl or Cassiaacutifolia Delile, plants of the Leguminosae family. It tastes sweet, bitter, and cold. It enters the large intestine meridian. It can relieve heat and relieve stagnation, promote bowel movements, and promote diuresis. It is used for heat stagnation, constipation, abdominal pain, and edema.
[0022] The present invention also relates to a method for preparing the above composition, comprising the following steps:
[0023] (1) Mixing Pu'er tea with water and heating for extraction, concentrating the extract, adding ethanol to the concentrate, stirring for extraction, filtering, and drying the filter cake to obtain a Pu'er tea extract;
[0024] (2) crushing and mixing Danshen, Astragalus, Poria, lotus leaf and senna leaf, soaking them in solution 1, filtering and obtaining extract 1 and extract residue;
[0025] (3) mixing the extraction residue, the complex enzyme and water, performing enzymolysis, heating extraction and filtering to obtain an extract 2;
[0026] (4) The extract 1 and the extract 2 are concentrated and dried respectively, and then mixed with the Pu'er tea extract and auxiliary materials to obtain the composition.
[0027] Preferably, in step (1), the mass ratio of water to Pu'er tea is 1:15-25, the temperature of the heating extraction is 90-100°C, the time of the heating extraction is 2-4h, the number of heating extractions is 2-4 times, the extract is concentrated to a mass volume ratio of tea leaves to concentrated solution of 1g:0.5-3mL, the mass ratio of ethanol to concentrated solution is 1:5-10, the number of stirring extractions is 1-2 times, and the time of stirring extraction is 0.5-1h.
[0028] Preferably, the solution 1 in step (2) is a mixed solution of ethanol, water and malic acid, the mass ratio of ethanol, water and malic acid is 1:3-4:0.3-0.5, the added amount of the solution 1 is 3-5 times the total mass of salvia miltiorrhiza, astragalus, poria, lotus leaf and senna leaf, the soaking temperature is 80-90°C, and the soaking time is 5-6h.
[0029] Preferably, the complex enzyme in step (3) is a mixture of cellulase, pectinase and xylanase, the mass ratio of the cellulase, pectinase and xylanase is 6-8:0.5-1:1-2, the amount of water added is 3-4 times the mass of the extraction residue, and the amount of the complex enzyme added is 2%-4% of the mass of the extraction residue.
[0030] Preferably, in step (3), the temperature of the enzymatic hydrolysis is 45-50°C, the pH of the enzymatic hydrolysis is 4.5-5.0, the time of the enzymatic hydrolysis is 1-3h, the temperature of the heating extraction is 80-90°C, and the time of the heating extraction is 1-3h.
[0031] The present invention also relates to the use of the above composition or the composition prepared by the above preparation method in the preparation of weight loss products.
[0032] The formula of the present invention is based on the principle of syndrome differentiation and treatment of traditional Chinese medicine. Pu'er tea can relieve greasiness, bitterness, expel phlegm and lower qi, and facilitate bowel movements; Danshen and Huangqi can promote blood circulation and dissipate blood stasis, invigorate qi and strengthen the spleen; lotus leaf can clear away heat and promote the clear yang; Poria can promote diuresis and eliminate dampness; Senna leaf can eliminate heat and relieve stagnation, relieve constipation and promote diuresis; the whole formula can be used together to promote blood circulation and dissipate blood stasis, strengthen fat and replenish the middle, promote diuresis and eliminate dampness, clear away heat and release heat, remove turbidity and reduce fat, moisten the intestines and relieve constipation, and achieve the health care effect of weight loss. In addition, Pu'er tea in the formula can reduce the synthesis of fat by regulating lipid synthesis-related genes, effectively inhibit fat absorption in the digestive tract, and increase fat discharge. The flavonoid components in lotus leaf can inactivate pancreatic lipase, reduce the conversion of fat into absorbable free fatty acids and monoacylglycerol, thereby reducing calorie intake and controlling body weight.
[0033] The Pu'er tea extract, Poria cocos extract and lotus leaf extract in the formula of the present invention have the weight-loss effect of removing excess fat in the body and inhibiting weight gain. When combined with senna leaf extract, salvia miltiorrhiza extract and astragalus extract, they can reduce weight while inhibiting the occurrence of obesity complications such as constipation and hyperlipidemia. The formula has an efficient and healthy weight-loss effect, which is unmatched by general weight-loss products.
[0034] This prescription is formulated based on a comprehensive analysis of the causes of obesity, symptoms of obesity, and the conditions of obese people, and is based on the theoretical research of traditional Chinese medicine, combined with the functional characteristics of chemical and natural products currently used in obesity. The prescription ingredients all have a certain weight loss effect, and can be targeted at the conditions of obese people, while also playing an auxiliary role in lowering blood lipids such as cholesterol and triglycerides, improving atherosclerosis and liver function, assisting in lowering blood pressure and blood sugar, and improving the sub-health status of obese people.
[0035] Compared with the prior art, the present invention has the following beneficial effects:
[0036] (1) The raw materials in the present invention are compatible and can be used together to accelerate the oxidation of fatty acids, remove excess fat and other fatty acid residues in the body, inhibit the activity of digestive enzymes, speed up the excretion of food, promote the conversion of fat, and accelerate the excretion of metabolic products of fat decomposition, which has a very good weight loss effect. In addition, pharmacological and toxicological studies have shown that this formula is safe and reliable, has the effect of weight loss, is highly targeted, and has a good effect.
[0037] (2) The raw materials used in the present invention are all items that can be used in health food, with sufficient supply and easy access, stable quality and convenient to take. Under the premise of ensuring safety and effectiveness, the cost is saved as much as possible, so as to maximize its due social benefits and economic value. DETAILED DESCRIPTION
[0038] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.
[0039] Cellulase, model CEL-01; pectinase, model FDY-2212; xylanase, model FFG-0652; all purchased from Xiasheng Biotechnology Development Co., Ltd.
[0040] Example 1
[0041] A composition with a weight loss effect, wherein the raw materials of the composition include, by weight: 5 parts of Pu'er tea, 4.5 parts of salvia miltiorrhiza, 4 parts of astragalus, 4 parts of poria, 1 part of lotus leaf, 0.33 parts of senna leaf, 2.234 parts of dextrin, 0.15 parts of citric acid and 0.05 parts of stevioside.
[0042] The preparation method of the above composition is:
[0043] (1) Mix Pu'er tea with 20 times water, heat at 95°C for 3 h, extract 3 times, combine the extracts, concentrate the extracts to Pu'er tea (weight): concentrate (volume) = 1 g: 1 mL, add 6 times ethanol to the concentrate, stir and extract 2 times, each time for 0.5 h, filter, and dry the filter cake to obtain Pu'er tea extract;
[0044] (2) Crush and mix Danshen, Astragalus, Poria, lotus leaf and senna leaf, add 4 times the mass of solution 1 (ethanol, water and malic acid in a mass ratio of 1:3.5:0.4), soak at 85°C for 5 h, filter and obtain extract 1 and extract residue;
[0045] (3) Mix the extract residue with 3.5 times the weight of water, add 3% of the weight of the extract residue (cellulase, pectinase and xylanase in a mass ratio of 6:1:1), perform enzymolysis at 48°C and pH 4.5 for 2 h, then heat and extract at 85°C for 2 h, filter, and obtain extract 2;
[0046] (4) The extract 1 and the extract 2 are concentrated and dried respectively, and then mixed with Pu'er tea extract, dextrin, citric acid and steviol glycoside to obtain the composition.
[0047] Example 2
[0048] A composition with a weight loss effect, wherein the raw materials of the composition include, by weight: 4 parts of Pu'er tea, 4 parts of salvia miltiorrhiza, 3 parts of astragalus, 3 parts of tuckahoe, 0.5 parts of lotus leaf, 0.2 parts of senna leaf, 2 parts of dextrin, 0.1 parts of citric acid and 0.02 parts of stevioside.
[0049] The preparation method of the above composition is:
[0050] (1) Mix Pu'er tea with 15 times water, heat at 90°C for 2 hours, extract twice, combine the extracts, concentrate the extracts to Pu'er tea (weight): concentrate (volume) = 1g:0.5mL, add 10 times ethanol to the concentrate, stir and extract once, extract for 1 hour, filter, and dry the filter cake to obtain Pu'er tea extract;
[0051] (2) Crush and mix Salvia miltiorrhiza, Astragalus membranaceus, Poria cocos, lotus leaf and senna leaf, add 3 times the mass of solution 1 (ethanol, water and malic acid in a mass ratio of 1:3:0.3), soak at 80°C for 6 h, filter and obtain extract 1 and extract residue;
[0052] (3) Mix the extract residue with 3 times the weight of water, add 2% of the weight of the extract residue (cellulase, pectinase and xylanase in a mass ratio of 6:0.5:1), perform enzymolysis at 45°C and pH 4.5 for 3 h, then heat and extract at 80°C for 3 h, filter and obtain extract 2;
[0053] (4) The extract 1 and the extract 2 are concentrated and dried respectively, and then mixed with Pu'er tea extract, dextrin, citric acid and steviol glycoside to obtain the composition.
[0054] Example 3
[0055] A composition with a weight loss effect, wherein the raw materials of the composition include, by weight: 6 parts of Pu'er tea, 5 parts of salvia miltiorrhiza, 5 parts of astragalus, 5 parts of poria, 1.5 parts of lotus leaf, 0.4 parts of senna leaf, 3 parts of dextrin, 0.2 parts of citric acid and 0.1 parts of stevioside.
[0056] The preparation method of the above composition is:
[0057] (1) Mix Pu'er tea with 25 times water, heat and extract at 100°C for 2 hours, extract twice, combine the extracts, concentrate the extracts to Pu'er tea (weight): concentrate (volume) = 1g:3mL, add 5 times ethanol to the concentrate, stir and extract twice, each time for 0.5 hours, filter, and dry the filter cake to obtain Pu'er tea extract;
[0058] (2) Crush and mix the salvia miltiorrhiza, astragalus, poria, lotus leaf and senna leaf, add 5 times the mass of solution 1 (ethanol, water and malic acid in a mass ratio of 1:4:0.5), soak at 90°C for 5 h, filter and obtain extract 1 and extract residue;
[0059] (3) Mix the extract residue with 4 times the weight of water, add 4% of the weight of the extract residue (cellulase, pectinase and xylanase in a mass ratio of 8:1:2), perform enzymolysis at 50°C and pH 5.0 for 1 h, then heat and extract at 90°C for 1 h, filter, and obtain extract 2;
[0060] (4) The extract 1 and the extract 2 are concentrated and dried respectively, and then mixed with Pu'er tea extract, dextrin, citric acid and steviol glycoside to obtain the composition.
[0061] Comparative Example 1
[0062] The difference between this comparative example and Example 1 is that the raw material ratio is different. In terms of weight, the raw materials of the composition are: 4 parts of Pu'er tea, 3 parts of Salvia miltiorrhiza, 5 parts of Astragalus, 2 parts of Poria, 2 parts of lotus leaf, 0.2 parts of senna leaf, 2.234 parts of dextrin, 0.15 parts of citric acid and 0.05 parts of stevioside.
[0063] Comparative Example 2
[0064] The difference between this comparative example and Example 1 is only that the preparation method is different.
[0065] The preparation method is:
[0066] (1) Pu'er tea, salvia miltiorrhiza, astragalus, poria, lotus leaf and senna leaf were crushed and mixed, and 4 times the mass of solution 1 (ethanol, water and malic acid in a mass ratio of 1:3.5:0.4) was added, and the mixture was soaked at 85°C for 5 hours, and filtered to obtain extract 1 and extract residue;
[0067] (2) Mix the extract residue with 3.5 times the weight of water, add 3% of the weight of the extract residue (cellulase, pectinase and xylanase in a mass ratio of 6:1:1), perform enzymolysis at 48°C and pH 4.5 for 2 h, then heat and extract at 85°C for 2 h, filter and obtain extract 2;
[0068] (3) The extract 1 and the extract 2 are concentrated and dried respectively, and mixed with dextrin, citric acid and steviol glycoside to obtain the composition.
[0069] Comparative Example 3
[0070] The difference between this comparative example and Example 1 is that the preparation method is different. Specifically, the composition of solution 1 in step (2) is only ethanol and water in a mass ratio of 1:3.5, and the other steps are consistent with Example 1.
[0071] Comparative Example 4
[0072] The difference between this comparative example and Example 1 is that the preparation method is different. Specifically, the composition of solution 1 in step (2) is only water and malic acid in a mass ratio of 3.5:0.4, and the other steps are consistent with Example 1.
[0073] Comparative Example 5
[0074] The difference between this comparative example and Example 1 is that the preparation method is different. Specifically, in step (3), the composite enzyme is only cellulase and pectinase in a mass ratio of 6:1, and the other steps are consistent with Example 1.
[0075] Comparative Example 6
[0076] The difference between this comparative example and Example 1 is that the preparation method is different. Specifically, in step (3), the composite enzyme is only cellulase and xylanase in a mass ratio of 6:1, and the other steps are consistent with Example 1.
[0077] Effect test
[0078] Test Example 1 Animal Experiment on Weight Loss Function
[0079] 1.1 Sample
[0080] The compositions of Examples 1-3 and Comparative Examples 1-6 are provided by Jilin Huakang Shiyuan Biotechnology Co., Ltd. The recommended oral dosage for humans is once a day, 1 bag each time, and the equivalent dosage is 0.083 g / kg·bw calculated based on an adult body weight of 60 kg.
[0081] 1.2 Experimental animals
[0082] A total of 170 healthy SPF male SD rats bred by the China Food and Drug Administration were selected, with license number SCXK-(Beijing) 2009-0017. The experimental animals were kept in the SPF animal room of the Health Food Function Testing Center of the School of Applied Arts and Sciences, Beijing Union University, with license number SYXK (Beijing) 2012-0031.
[0083] 1.3 Animal feed
[0084] High-calorie model feed and maintenance feed produced by Beijing Huafukang Biotechnology Co., Ltd. were selected. The formula of high-calorie model feed was: 60% basic feed, 15% lard, 15% sucrose, 8% casein, and 2% calcium hydrogen phosphate.
[0085] 1.4 Dosage groups and test sample administration time
[0086] Dose grouping and test sample administration time: The experiment set up three dose groups of high, medium and low in Example 1, groups of Example 2-3, comparative examples 1-6, blank control group and model control group. The low, medium and high doses of the sample in Example 1 were 0.21g / kg·bw, 0.42g / kg·bw and 1.25g / kg·bw respectively (equivalent to 2.5 times, 5 times and 15 times the recommended dose for human body respectively), and the dosages of Examples 2-3 and Comparative Examples 1-6 were the same as those of the high dose group in Example 1.
[0087] The preparation method of the three dose groups of Example 1, high, medium and low, is as follows: 25.00 g of sample is added with sterile water to 100 mL as the high dose test substance, and the medium and low dose test substances are diluted with the high dose test substance: sterile water at a ratio of 1:2 and 1:5. The blank control and model control groups are given an equal volume of distilled water. The test animals are given oral administration, respectively, with an oral administration volume of 0.5 mL / 100 g·bw, once a day, and various indicators are observed after continuous oral administration for 44 days.
[0088] 1.5 Experimental methods
[0089] After the adaptation period, 170 rats were randomly divided into 2 groups according to body weight, of which 10 rats were given maintenance feed as a blank control group, and 160 rats were given a high-calorie model feed. After feeding for 14 days, the rats given the high-calorie model feed were sorted according to weight gain, and 140 obesity-sensitive rats were screened out and randomly divided into 14 groups according to body weight, namely, a model control group, three dose groups of low, medium and high doses of the sample in Example 1, Example 2-3 groups and Comparative Example 1-6 groups, 10 rats in each group.
[0090] Since the beginning of the experiment, each animal in the model control group and each dose group was given an equal amount of high-calorie model feed every day (the amount of feed given was based on the principle that most animals had finished eating it), and the blank control group was given maintenance feed in the same way, and the amount of feed given was the same as the high-calorie model feed. Each dose group was given different doses of the test substance, and the blank control group and the model control group were given sterile water. During the experiment, the amount of food given, the amount of food left, and the amount of food spilled by each animal was recorded every week, and the body weight was weighed once a week. The body weight was weighed 44 days after the test substance was given, and the body fat (testicular and perirenal fat pads) was taken and weighed to calculate the fat / body ratio.
[0091] 1.6 Observation indicators
[0092] Body weight, weight gain, food intake, total calorie intake (food intake × calories per kg of feed), food utilization, body fat weight (testicular and perirenal fat pads), and fat / body ratio.
[0093] 1.7 Data Processing
[0094] The data were statistically analyzed using Excel 2003 and Spss11.0 software. The data were first tested for homogeneity of variance. If the variance was homogeneous, one-way analysis of variance was used for overall comparison. If differences were found, the Dunnett method was used to compare the means of multiple dose groups with a model control group. If the variance was not homogeneous, the original data were appropriately transformed. After the variance homogeneity test was met, the transformed data were used for statistics. If the variance was still not homogeneous after the variable transformation, the rank sum test was used for statistics. If the overall comparison was found to be different, the Tamhane's T2 test, which did not require homogeneity of variance, was used for pairwise comparison.
[0095] Before and after the establishment of the obesity model, the body weights of rats in the blank control group and the model control group were compared using the independent sample t-test.
[0096] 1.8 Result determination
[0097] The body weight or weight gain of each dose group was lower than that of the model control group, and the body fat weight or fat / body ratio was lower than that of the model control group. The difference was significant. The food intake was not significantly lower than that of the model control group. It can be judged that the experimental results of the weight loss function of the test sample animals were positive.
[0098] 2. Results
[0099] 2.1 Effects on weight gain and food utilization in obese rats
[0100] The test results are shown in Table 1.
[0101] Table 1 Effects on the body weight of obese rats
[0102]
[0103] Note: Compared with the blank control group, # P<0.05, ## P<0.01; compared with the model control group, P<0.05, P<0.01; compared with the high-dose group in Example 1, △ P<0.05.
[0104] As shown in Table 1, after 14 days of administration of the high-calorie model feed, the body weight of rats in the model control group, Example 1-3 groups and Comparative Example 1-6 groups increased significantly compared with the blank control group (P < 0.05), indicating that the model was successfully established. After 44 days of administration of the test substance, the body weight of rats in the model control group increased significantly compared with the blank control group (P < 0.01), and the final body weight of rats in the high-dose group of Example 1 and Example 2-3 groups decreased significantly compared with the model control group (P < 0.05).
[0105] After 44 days of administration of the test substance, the blank control group was compared with the model control group, and the weight gain and food utilization rate of the rats were significantly different (P < 0.01). Compared with the model control group, the weight gain of the rats in the medium-dose group of Example 1 and the comparative example 1-6 groups was significantly reduced (P < 0.05), and the food utilization rate was significantly reduced (P < 0.05); compared with the model control group, the weight gain of the rats in the high-dose group of Example 1 and the example 2-3 groups was significantly reduced (P < 0.01), and the food utilization rate was significantly reduced (P < 0.01).
[0106] 2.2 Effects on body fat weight and fat / body ratio in obese rats
[0107] The test results are shown in Table 2.
[0108] Table 2 Effects on body fat weight and fat / body ratio in obese rats
[0109]
[0110] Note: Compared with the model control group, P<0.05, P<0.01; compared with the high-dose group in Example 1, △ P<0.05.
[0111] As shown in Table 2, after 44 days of administration of the test substance, the body fat weight and fat / body ratio of rats in the blank control group were significantly different from those in the model control group (P < 0.01). Compared with the model control group, the body fat weight of rats in the high-dose group of Example 1 and the groups of Examples 2-3 were significantly reduced (P < 0.05), and the fat / body ratio was significantly reduced (P < 0.05).
[0112] 2.3 Effects on food intake and total calorie intake in obese rats
[0113] The test results are shown in Table 3.
[0114] Table 3 Effects on food intake and total calorie intake in obese rats
[0115]
[0116] Note: Compared with the model control group, P<0.05, P<0.01.
[0117] As shown in Table 3, 44 days after the administration of the test substance, there was no significant difference in the food intake of rats between the blank control group and the model control group (P>0.05), and there was a significant difference in the total calorie intake of rats (P<0.01). There was no significant difference in the food intake of rats between the experimental groups and the model control group (P>0.05), that is, the food intake of the experimental groups was relatively balanced; there was no significant difference in the total calorie intake of rats between the experimental groups and the model control group (P>0.05), that is, the total calorie intake of the obese model rats was relatively balanced.
[0118] Test Example 2 Human Food Tasting Experiment Report
[0119] 1. Sample
[0120] The composition of Example 1 is provided by Jilin Huakang Shiyuan Biotechnology Co., Ltd. The recommended oral dosage for human body is once a day, 1 bag each time, and the dosage is 5g / d.
[0121] 1.2 Subjects
[0122] 1.2.1 Subject inclusion criteria: simple obese people, adult BMI ≥ 30, or total fat percentage reaching male > 25% and female > 30% voluntary subjects.
[0123] 1.2.2 Subject Exclusion Criteria
[0124] Patients with serious diseases of the heart, liver, kidney and hematopoietic system, and mental illness.
[0125] Taking items related to the function being tested in the short term will affect the person who judges the results.
[0126] Those who fail to consume the test samples as required and whose efficacy cannot be determined or whose efficacy or safety judgment is affected by incomplete data.
[0127] 1.3 Experimental design and grouping
[0128] The weight loss function test without replacing staple food adopts self-control and inter-group control test design. The subjects are randomly divided into a trial group and a control group according to their body weight and body fat weight. The main factors affecting the results such as age, gender, diet, exercise status, etc. are considered as much as possible, and a balance test is conducted to ensure the comparability between the groups. Each group has no less than 50 subjects.
[0129] 1.4 Dosage and time of consumption
[0130] For the weight loss test samples that do not replace staple food, the test group takes the test product according to the recommended method and dosage, and the control group uses a blank control. The test test is conducted in a blind method. Take it once a day with a dosage of 5g / d, and the test sample is given for at least 60 days.
[0131] 1.5 Instruments and reagents
[0132] ModularP fully automatic biochemical analyzer (Roche Diagnostics, Germany); TBA-120 fully automatic biochemical analyzer (TOSHIBA, Japan); Clinitek Advantus urine analyzer (SIEMENS); Sysmex-K21 three-category blood analyzer (Sysmex); TANITA body fat analyzer (made in Japan), MONARK-828E power bicycle (made in Sweden), Sysmex blood cell analysis diluent (Sysmex); Multistix 10SG urine analysis reagent strip (SIEMENS); the biochemical test kit was produced by Roche Diagnostics GmbH, Germany, and provided by Roche Diagnostics Products (Shanghai) Co., Ltd., Germany.
[0133] 2. Observation indicators
[0134] 2.1 Safety indicators
[0135] 2.1.1 General condition: including mental state, sleep, diet, urination and defecation, blood pressure, heart rate, etc.
[0136] 2.1.2 Routine examination of blood, urine and stool: red blood cell count, hemoglobin, white blood cell count, routine urine and stool examination.
[0137] 2.1.3 Blood biochemical examination (including liver and kidney function examination): serum albumin, total protein, aspartate aminotransferase, alanine aminotransferase, total bilirubin, urea, creatinine, uric acid, blood glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol, etc.
[0138] 2.1.4 Chest X-ray, electrocardiogram, and abdominal B-ultrasound examination (each index should be checked once before the test)
[0139] 2.1.5 Serum uric acid and urine ketones
[0140] 2.1.6 Observation of dietary factors and exercise status
[0141] For weight loss tests that do not replace staple foods, a three-day dietary survey of the subjects is required before and after the start of the test. In order to eliminate the impact of dietary factors on the test results, the diet should be as consistent as possible with the daily diet. During the test, the subjects' exercise status should be inquired and observed, which should be consistent with their daily exercise status.
[0142] 2.1.7 Sports endurance test
[0143] The exercise endurance test method was a power bicycle test. Before and after the food trial, the subjects performed a power bicycle test with the same exercise program, recorded their heart rate, and used the nomogram method of Astrand and Ryhming to indirectly determine the maximum oxygen uptake (L / min) of each subject.
[0144] 2.1.8 Observation of other adverse reactions: such as anorexia, diarrhea, etc.
[0145] 2.2 Efficacy indicators
[0146] 2.2.1 Weight, height, waist circumference (around the navel), hip circumference, and calculate body mass index (BMI), standard weight, and overweight.
[0147] Adult (BMI) = ;
[0148] Overweight (%) = .
[0149] 2.2.2 Determination of body fat content
[0150] The total amount of body fat and the percentage of fat to body weight are measured using underwater weighing or electrical impedance method.
[0151] Subcutaneous fat thickness is measured by B-ultrasound or skin caliper method, and the 4 measurement sites are as follows:
[0152] Point A: The midpoint of the outer side of the arm at the lower edge of the right deltoid muscle; Point B: The lower angle of the right scapula; Point C: 3cm beside the right navel; Point D: The right anterior superior iliac spine.
[0153] 2.2.3 Symptom observation
[0154] The integral method was used, with subjective symptoms such as diet, sleep, defecation, urination, fatigue, sweating, and constipation as indicators. A questionnaire was used to calculate the integral values before and after the tasting according to the severity of each symptom (3 points for severe symptoms, 2 points for moderate symptoms, and 1 point for mild symptoms). The improvement rate was calculated based on the improvement of the main symptoms (an improvement of 2 points for each symptom was considered significant, and an improvement of 1 point was considered effective).
[0155] 3. Data processing and result determination
[0156] 3.1 Data processing
[0157] The statistical software SPSS was used to calculate and analyze the data. The experimental data were quantitative data and could be analyzed using the t-test. Paired t-tests could be used for self-control data, and grouped t-tests were used for comparison of the means of two groups. The latter required a variance homogeneity test. Appropriate variable transformation was performed for data with non-normal distribution or uneven variance. After the normal variance homogeneity was met, the transformed data was used for the t-test. If the transformed data still could not meet the normal variance homogeneity requirement, the t-test or rank sum test was used instead. However, the rank sum test was used for data with a large coefficient of variation (such as CV>50%).
[0158] 3.2 Efficacy criteria
[0159] Effective: The test sample with weight loss function that does not replace the staple food: the test group was compared with itself and compared with the control group after the tasting, and its body fat weight was reduced, at least two of the four points of subcutaneous fat were reduced, and one of the waist circumference and hip circumference was reduced, and the difference was significant (P < 0.05), the exercise endurance did not decrease, and there was no adverse effect on the health of the body, and the influence of diet and exercise on the weight loss function was ruled out. It can be determined that the test sample has the weight loss function.
[0160] Invalid: Failed to meet the above criteria.
[0161] 4 Results
[0162] 4.1 General Condition
[0163] A total of 125 subjects were included, and 124 were effective subjects. There were 62 subjects in the trial group and 62 subjects in the control group. Before the trial, the subjects' blood routine, urine routine, stool routine, liver and kidney function, chest X-ray, electrocardiogram, B-ultrasound and other examinations were all within the normal range. The grouping is shown in Table 4. Before the trial, there was no significant difference in age, gender, fat time, body mass index and fat percentage between the two groups (P>0.05), which was comparable. There was no significant change in the spirit, sleep, diet, defecation, blood pressure and heart rate of the subjects before and after the trial.
[0164] Table 4 Comparison of general information before tasting
[0165]
[0166] 4.2 Changes in body weight, body mass index, overweight, body fat mass, and fat percentage
[0167] 4.2.1 Changes in weight, body mass index, and overweight
[0168] The test results are shown in Tables 5 to 7.
[0169] Table 5 Changes in body weight before and after the test
[0170]
[0171] Note: Self-comparison, P<0.001; comparison between groups, ## P<0.01, ### P<0.001.
[0172] Table 6 Changes in BMI before and after the diet
[0173]
[0174] Note: Self-comparison, P<0.001; comparison between groups, ### P<0.001.
[0175] Table 7 Changes in overweight before and after the trial
[0176]
[0177] Note: Self-comparison, P<0.001; comparison between groups, ### P<0.001.
[0178] 4.2.2 Changes in body fat mass and fat percentage
[0179] The test results are shown in Tables 8 and 9.
[0180] Table 8 Changes in body fat before and after the diet
[0181]
[0182] Note: Self-comparison, P<0.001; comparison between groups, ### P<0.001.
[0183] Table 9 Changes in fat percentage before and after the trial
[0184]
[0185] Note: Self-comparison, P<0.01; comparison between groups, ## P<0.01, ### P<0.001.
[0186] 4.3 Changes in waist and hip circumference
[0187] 4.3.1 Changes in waist circumference
[0188] The test results are shown in Table 10.
[0189] Table 10 Changes in waist circumference before and after the food trial
[0190]
[0191] Note: Self-comparison, P<0.01; comparison between groups, # P<0.05, ## P<0.01.
[0192] 4.3.2 Changes in hip circumference
[0193] The test results are shown in Table 11.
[0194] Table 11 Changes in hip circumference before and after the food trial
[0195]
[0196] Note: Self-comparison, P<0.001; comparison between groups, ### P<0.001.
[0197] 4.4 Changes in subcutaneous fat thickness
[0198] The test results are shown in Table 12.
[0199] Table 12 Changes in subcutaneous fat thickness
[0200]
[0201] Note: Self-comparison, P<0.001; comparison between groups, ### P<0.001.
[0202] 4.5 Improvement of main symptoms
[0203] The test results are shown in Table 13.
[0204] Table 13 Improvement of main symptoms
[0205]
[0206] Note: ( ) outside represents the test group, ( ) inside represents the control group.
[0207] 4.6 Safety index detection
[0208] 4.6.1 Changes in maximum oxygen consumption and comparison of dietary calories
[0209] The test results are shown in Tables 14 and 15.
[0210] Table 14 Changes in maximum oxygen consumption before and after the test
[0211]
[0212] Note: Self-comparison, P<0.01.
[0213] Table 15 Comparison of dietary calories before and after the trial
[0214]
[0215] Comparison of dietary calories within and between groups before and after the experiment, P>0.05.
[0216] 4.6.2 Routine blood, urine, stool and blood biochemical indicators before and after the trial
[0217] The test results are shown in Table 16.
[0218] Table 16 Changes in blood, urine, stool routine and blood biochemical indicators before and after the trial
[0219]
[0220] All the above indicators were basically within the normal range before and after the test.
[0221] 4.6.3 Comparison of heart rate and blood pressure
[0222] The test results are shown in Table 17.
[0223] Table 17 Comparison of heart rate and blood pressure before and after the tasting
[0224]
[0225] There was basically no significant change in heart rate and blood pressure before and after the experiment.
[0226] 4.6.4 Before the trial, the abdominal ultrasound, electrocardiogram and chest X-ray were basically within the normal range.
[0227] 4.7 Dropout rate of subjects
[0228] A total of 125 subjects were included, including 62 in the trial group and 63 in the control group. Among them, 1 subject in the control group did not undergo follow-up examination at the prescribed time at the end of the trial; the subjects who met the exclusion criteria were 62 in the trial group and 62 in the control group, and the dropout rates of the trial group and the control group were 0.0% and 1.6%, respectively.
[0229] 4.8 Adverse reaction observation: No allergic reaction or other adverse reactions were observed.
[0230] The test results are shown in Table 18.
[0231] Table 18 Adverse reactions and allergic reactions in the two groups during the trial period
[0232]
[0233] 5. Summary
[0234] 125 simple obese subjects were randomly divided into a trial group and a control group by double-blind method. 124 cases were effective, 62 cases were in the trial group, and 62 cases were in the control group. The trial group took the granules of the composition of Example 1 of the present invention, and the control group was a blank control. After 60 days, the average weight of the trial group decreased by (4.11±4.33) kg, P<0.001; the body fat mass decreased by (3.91±4.89) kg, P<0.001; the body fat percentage decreased by (2.47±4.01)%, P<0.001; the waist circumference decreased by (2.23±6.47) cm, P<0.01; the hip circumference decreased by (2.40±4.02) cm, P<0.001; the BMI decreased by (P <0.001), the thickness of the lower edge of the right deltoid muscle at the midpoint of the outer side of the arm was reduced (P<0.001), the right inferior angle of the scapula was reduced (P<0.001), and the thickness of the subcutaneous fat 3 cm beside the right umbilicus and the right anterior superior iliac spine was reduced (P<0.001). Compared with the control group, the trial group had a decrease in body weight (P<0.01), body fat mass (P<0.001), body fat percentage (P<0.01), waist circumference (P<0.5), and the thickness of the subcutaneous fat at the right anterior superior iliac spine and the right inferior angle of the scapula was also reduced (P<0.05).
[0235] The chest X-ray, abdominal B-ultrasound and electrocardiogram of the test subjects were basically within the normal range. Before and after the test of the granules of the composition of Example 1 of the present invention, the blood routine, urine routine, stool routine and blood biochemical indexes were all within the normal range, indicating that this product has no adverse effects on the health of the test subjects.
[0236] No allergic or other adverse reactions were observed during the tasting of the granules of the composition of Example 1 of the present invention.
[0237] The above detailed description is a specific description of one feasible embodiment of the present invention. The embodiment is not intended to limit the patent scope of the present invention. Any equivalent implementation or modification that does not deviate from the present invention should be included in the scope of the technical solution of the present invention.
Claims
1. A composition having a weight loss effect, characterized in that: The composition is composed of Chinese medicinal raw materials and auxiliary materials. The Chinese medicinal raw materials are: 4-6 parts of Pu'er tea, 4-5 parts of Salvia miltiorrhiza, 3-5 parts of Astragalus, 3-5 parts of Poria, 0.5-1.5 parts of lotus leaves and 0.2-0.4 parts of senna leaves by weight. The preparation method of the above composition comprises the following steps: (1) Mixing Pu'er tea with water and heating for extraction, concentrating the extract, adding ethanol to the concentrate, stirring for extraction, filtering, and drying the filter cake to obtain a Pu'er tea extract; (2) crushing and mixing Danshen, Astragalus, Poria, lotus leaf and senna leaf, soaking them in solution 1, filtering and obtaining extract 1 and extract residue; (3) mixing the extraction residue, the complex enzyme and water, performing enzymolysis, heating extraction and filtering to obtain an extract 2; (4) Concentrating and drying the extract 1 and the extract 2 respectively, and then mixing them with the Pu'er tea extract and the auxiliary materials to obtain the composition; Wherein, the solution 1 in step (2) is a mixed solution of ethanol, water and malic acid, and the mass ratio of ethanol, water and malic acid is 1:3-4:0.3-0.5; The complex enzyme in step (3) is a mixture of cellulase, pectinase and xylanase, and the mass ratio of the cellulase, pectinase and xylanase is 6-8:0.5-1:1-2.
2. The composition according to claim 1, characterized in that In terms of weight, the Chinese medicinal raw materials are: 5 parts of Pu'er tea, 4.5 parts of Salvia miltiorrhiza, 4 parts of Astragalus, 4 parts of Poria, 1 part of lotus leaf and 0.33 parts of senna leaf.
3. The composition according to any one of claims 1 to 2, characterized in that The auxiliary materials are dextrin, citric acid and steviol glycoside.
4. The composition according to claim 3, characterized in that In terms of weight, the auxiliary materials include: 2-3 parts of dextrin, 0.1-0.2 parts of citric acid and 0.02-0.1 parts of stevioside.
5. A method for preparing the composition according to any one of claims 1 to 4, characterized in that: The following steps are involved: (1) Mixing Pu'er tea with water and heating for extraction, concentrating the extract, adding ethanol to the concentrate, stirring for extraction, filtering, and drying the filter cake to obtain a Pu'er tea extract; (2) crushing and mixing Danshen, Astragalus, Poria, lotus leaf and senna leaf, soaking them in solution 1, filtering and obtaining extract 1 and extract residue; (3) mixing the extraction residue, the complex enzyme and water, performing enzymolysis, heating extraction and filtering to obtain an extract 2; (4) Concentrating and drying the extract 1 and the extract 2 respectively, and then mixing them with the Pu'er tea extract and the auxiliary materials to obtain the composition; Wherein, the solution 1 in step (2) is a mixed solution of ethanol, water and malic acid, and the mass ratio of ethanol, water and malic acid is 1:3-4:0.3-0.5; The complex enzyme in step (3) is a mixture of cellulase, pectinase and xylanase, and the mass ratio of the cellulase, pectinase and xylanase is 6-8:0.5-1:1-2.
6. The preparation method according to claim 5, characterized in that: In step (1), the mass ratio of water to Pu'er tea is 1:15-25, the temperature of heating extraction is 90-100°C, the time of heating extraction is 2-4h, the number of heating extractions is 2-4 times, the extract is concentrated to a mass volume ratio of tea leaves to concentrated solution of 1g:0.5-3mL, the mass ratio of ethanol to concentrated solution is 1:5-10, the number of stirring extractions is 1-2 times, and the time of stirring extraction is 0.5-1h.
7. The preparation method according to claim 5, characterized in that: In step (2), the amount of solution 1 added is 3-5 times the total mass of salvia miltiorrhiza, astragalus, poria, lotus leaf and senna leaf, the soaking temperature is 80-90° C., and the soaking time is 5-6 hours.
8. The preparation method according to claim 5, characterized in that: In step (3), the amount of water added is 3-4 times the mass of the extraction residue, and the amount of the complex enzyme added is 2%-4% of the mass of the extraction residue.
9. The preparation method according to claim 5, characterized in that: In step (3), the enzymatic hydrolysis temperature is 45-50°C, the enzymatic hydrolysis pH is 4.5-5.0, the enzymatic hydrolysis time is 1-3h, the heating extraction temperature is 80-90°C, and the heating extraction time is 1-3h.
10. Use of the composition according to any one of claims 1 to 4 or the composition prepared by the preparation method according to any one of claims 5 to 9 in preparing a weight loss product.
